Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497415 | 0.89 | EPHX2 (0.54) | EPHX2FAAHCNR2FKBP1ACNR1 | |
| SCHEMBL1497397 | 0.83 | FAAH (0.53) | EPHX2FAAHCNR2FKBP1ACNR1 | |
| SCHEMBL13575195 | 0.81 | EPHX2 (0.52) | EPHX2FAAHCNR2FKBP1ACNR1 | |
| SCHEMBL13575194 | 0.81 | EPHX2 (0.52) | EPHX2FAAHCNR2FKBP1ACNR1 | |
| SCHEMBL1556682 | 0.81 | EPHX2 (0.52) | EPHX2FAAHCNR2FKBP1ACNR1 | |
| SCHEMBL17787705 | 0.81 | EPHX2 (0.52) | EPHX2FAAHCNR2FKBP1ACNR1 | |
| SCHEMBL16665110 | 0.81 | EPHX2 (0.53) | EPHX2FAAHCNR2FKBP1ACNR1 | |
| SCHEMBL10297219 | 0.81 | EPHX2 (0.51) | EPHX2FAAHCNR2FKBP1ACNR1 | |
| SCHEMBL974457 | 0.81 | EPHX2 (0.51) | EPHX2FAAHCNR2FKBP1ACNR1 | |
| SCHEMBL973910 | 0.81 | EPHX2 (0.51) | EPHX2FAAHCNR2FKBP1ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440720-B2 | Methods of use of antiviral compounds | INFLUMEDIX, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440720-B2 | Methods of use of antiviral compounds | INFLUMEDIX, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | MAVS, SLC30A5, HAVCR2 | EPHX2 3743/4885FAAH 2661/4885CNR2 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.